Where can I find news about 207940.KS?

The latest press releases, SEC filings, and earnings call transcripts for Samsung Biologics Co.,Ltd. (207940.KS) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.

Where are 207940.KS's SEC filings?

Samsung Biologics Co.,Ltd. (207940.KS)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

When was 207940.KS's last earnings call?

The most recent earnings call transcript for Samsung Biologics Co.,Ltd. (207940.KS) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

207940.KS

Samsung Biologics Co.,Ltd.

KSC·Biotechnology · Healthcare

₩1,377,000₩5,000+0.36%

Market cap₩63.74T·Market closed·Jul 23 6:06 AM UTC

Press Releases

Samsung Biologics Reports Second Quarter 2026 Financial Results
/PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the
prnewswire.comJul 22, 2026 · 7:03 PM
Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury shares) at
prnewswire.comJul 19, 2026 · 6:43 PM
Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth
/PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), published its annual environmental,
prnewswire.comJun 30, 2026 · 7:00 AM

SEC Filings

No recent filings indexed.

Transcripts

PRO

Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.

Click below to see what's inside, then upgrade to read every transcript for 207940.KS and 80,000+ other tickers.

Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.

Frequently Asked Questions About 207940.KS

Where can I find news about 207940.KS?: The latest press releases, SEC filings, and earnings call transcripts for Samsung Biologics Co.,Ltd. (207940.KS) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.
Where are 207940.KS's SEC filings?: Samsung Biologics Co.,Ltd. (207940.KS)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
When was 207940.KS's last earnings call?: The most recent earnings call transcript for Samsung Biologics Co.,Ltd. (207940.KS) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

Samsung Biologics Co.,Ltd.

Frequently Asked Questions About 207940.KS

Samsung Biologics Co.,Ltd.

Samsung Biologics Reports Second Quarter 2026 Financial Results

Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India

Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth

Frequently Asked Questions About 207940.KS

Samsung Biologics Reports Second Quarter 2026 Financial Results

Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India

Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth